Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 2157-2166

  Liu, Ran Yi ^a,c   Dong, Zizheng ^a   Liu, Jianguo ^a   Zhou, Ling ^c   Huang, Wenlin ^c   Khoo, Sok Kean ^d   Zhang, Zhongfa ^d   Petillo, David ^d   Teh, Bin Tean ^d,e   Qian, Chao Nan ^c   Zhang, Jian Ting ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMMONIA LIGASE; CHORIONIC GONADOTROPIN ALPHA SUBUNIT; CISPLATIN; EUKARYOTIC INITIATION FACTOR 3A; INITIATION FACTOR 3; MATRIX METALLOPROTEINASE 19; MOLECULAR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; ARTICLE; ASNS GENE; CANCER CELL CULTURE; CANCER PATIENT; CGA GENE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG SENSITIVITY; EXCISION REPAIR; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MMP19 GENE; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; UPREGULATION;

ASPARTATE-AMMONIA LIGASE; BIOMARKERS, PHARMACOLOGICAL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES, SECRETED; NASOPHARYNGEAL NEOPLASMS;

EID: 84885605346     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1190     Document Type: Article

References (46)

1. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer 2012;31: 185-96.
2. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 2011;30: 114-9.
3. Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a "Cantonese cancer"? Chin J Cancer 2010;29: 517-26.
4. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64: 47-56.
5. Thephamongkhol K, Zhou J, Browman G, Wong R, Chan J, Zeng Y, et al. Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: a meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases. J Clin Oncol 2004;22:493s.
6. Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu X, et al. Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Oncogene 2011;30: 4814-23.
7. Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 2006;5: 2613-23.
8. Hegedus L, Cho H, Xie X, Eliceiri GL. Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J Cell Physiol 2008;216: 480-5.
9. Sizhong Z, Xiukung G, Yi Z. Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma. Int J Cancer 1983;31: 587-90.
10. Yang Y, Chen Q, Zhang JT. Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1. J Biol Chem 2002;277: 44268-77.
11. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001;98: 9754-9.
12. Gray SG, Qian CN, Furge K, Guo X, Teh BT. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 2004;24: 773-95.
13. Guo X, LuiWO,Qian CN, Chen JD, Gray SG, Rhodes D, et al. Identifying cancer-related genes in nasopharyngeal carcinoma cell lines using DNA and mRNA expression profiling analyses. Int J Oncol 2002;21: 1197-204.
14. Dong Z, Liu Z, Cui P, Pincheira R, Yang Y, Liu J, et al. Role of eIF3a in regulating cell cycle progression. Exp Cell Res 2009;315: 1889-94.
15. Peng H, Dong Z, Qi J, Yang Y, Liu Y, Li Z, et al.A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS ONE 2009;4:e5676.
16. Liu H, Liu Y, Zhang JT. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther 2008;7: 263-70.
17. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273: 5858-68.
18. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53: 3976-85.
19. Kong L, Zhang YW, Hu CS, Guo Y. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma. Chin J Cancer 2010;29: 551-5.
20. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002;42: 317-25.
21. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998;34: 1522-34.
22. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14: 1291-5.
23. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33: 9-23.
24. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4: 307-20.
25. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451: 1111-5.
26. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451: 1116-20.
27. Shah NP. Bench to bedside: BRCA: from therapeutic target to therapeutic shield. Nat Med 2008;14: 495-6.
28. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7: 573-84.
29. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 2010;77: 887-94.
30. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007;26: 71-83.
31. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22: 7265-79.
32. Richards NG, Schuster SM. Mechanistic issues in asparagine synthetase catalysis. Adv Enzymol Relat Areas Mol Biol 1998;72: 145-98.
33. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on erwinia asparaginase. Cancer 2011;117: 238-49.
34. Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 2006;1: 241-54.
35. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28: 97-113.
36. Cui H, Darmanin S, Natsuisaka M, Kondo T, Asaka M, Shindoh M, et al. Enhanced expression of asparagine synthetase under glucosedeprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res 2007;67: 3345-55.
37. Pendas AM, Knauper V, Puente XS, Llano E, Mattei MG, Apte S, et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997;272: 4281-6.
38. Mueller MS, Mauch S, Sedlacek R. Structure of the human MMP-19 gene. Gene 2000;252: 27-37.
39. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8: 221-33.
40. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141: 52-67.
41. Lu J, Chua HH, Chen SY, Chen JY, Tsai CH. Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 2003; 63: 256-62.
42. Chan KC, Ko JM, Lung HL, Sedlacek R, Zhang ZF, Luo DZ, et al. Catalytic activity of matrix metalloproteinase-19 is essential for tumor suppressor and anti-angiogenic activities in nasopharyngeal carcinoma. Int J Cancer 2011;129: 1826-37.
43. Velinov N, Aebersold D, Haeni N, Hlushchuk R, Mishev G, Weinstein F, et al. Matrix metalloproteinase-19 is a predictive marker for tumor invasiveness in patients with oropharyngeal squamous cell carcinoma. Int J Biol Markers 2007;22: 265-73.
44. Muller M, Beck IM, Gadesmann J, Karschuk N, Paschen A, Proksch E, et al. MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells. Mod Pathol 2010;23: 511-21.
45. Lettau I, Hattermann K, Held-Feindt J, Brauer R, Sedlacek R, Mentlein R. Matrix metalloproteinase-19 is highly expressed in astroglial tumors and promotes invasion of glioma cells. J Neuropathol Exp Neurol 2010;69: 215-23.
46. Ansell A, Jerhammar F, Ceder R, Grafstrom R, Grenman R, Roberg K. Matrix metalloproteinase-7 and -13 expression associate to cisplatin resistance in head and neck cancer cell lines. Oral Oncol 2009;45: 866-71.